Silverarc Capital Management, LLC 13F holdings, Q2 2025
Holdings as of June 30, 2025 · filings on SEC EDGAR · latest filing →
Silverarc Capital Management, LLC disclosed 57 US equity positions worth $488.6m in its Q2 2025 13F filing. The largest position was MERUS N V at 8.0% of the reported book, followed by AKERO THERAPEUTICS INC and VRNA. Against the Q1 2025 filing, it opened 9 new positions, added to 17 and reduced 19 among the top 50 holdings.
What did Silverarc Capital Management, LLC own in Q2 2025? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2025 |
|---|---|---|---|---|---|---|---|
| 1 | MERUS N V | 8.0% | $39.0m | 741,972 | -9% | reduced | |
| 2 | AKERO THERAPEUTICS INC | 7.8% | $38.1m | 713,811 | -1% | reduced | |
| 3 | VRNA VERONA PHARMA PLC | 6.9% | $33.9m | 358,297 | -34% | reduced | |
| 4 | URGN UROGEN PHARMA LTD | Healthcare | 5.7% | $27.7m | 2,022,482 | 46% | added |
| 5 | RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 5.2% | $25.3m | 400,772 | 19% | added |
| 6 | INSM INSMED INC | Healthcare | 5.1% | $25.1m | 249,060 | -22% | reduced |
| 7 | 4XC1 KALVISTA PHARMACEUTICALS INC | 4.2% | $20.7m | 1,832,171 | 8% | added | |
| 8 | NBIX NEUROCRINE BIOSCIENCES INC | Healthcare | 4.2% | $20.5m | 162,969 | 125% | added |
| 9 | ETNBGBP 89BIO INC | 4.1% | $20.0m | 2,037,087 | 35% | added | |
| 10 | ORIC ORIC PHARMACEUTICALS INC | Healthcare | 3.7% | $18.3m | 1,800,829 | -13% | reduced |
| 11 | NUVALENT INC | 3.7% | $18.0m | 235,583 | -46% | reduced | |
| 12 | SLNOEUR SOLENO THERAPEUTICS INC | 3.5% | $17.1m | 204,591 | 23% | added | |
| 13 | ASND ASCENDIS PHARMA A/S | Healthcare | 3.1% | $14.9m | 86,552 | 14% | added |
| 14 | CGON CG ONCOLOGY INC | Healthcare | 2.9% | $14.1m | 541,034 | – | new |
| 15 | VCYT VERACYTE INC | Healthcare | 2.5% | $12.1m | 448,495 | -29% | reduced |
| 16 | SRRK SCHOLAR ROCK HLDG CORP | Healthcare | 2.5% | $12.1m | 341,010 | – | new |
| 17 | RNAGBP AVIDITY BIOSCIENCES INC | 2.4% | $11.6m | 410,000 | -0% | held | |
| 18 | PCVX VAXCYTE INC | Healthcare | 1.9% | $9.4m | 287,796 | – | new |
| 19 | PFE PFIZER INC | Healthcare | 1.7% | $8.3m | 344,338 | – | new |
| 20 | HELIX ACQUISITION CORP II | 1.3% | $6.5m | 613,393 | 0% | held | |
| 21 | GOSS GOSSAMER BIO INC | Healthcare | 1.3% | $6.3m | 5,146,782 | -19% | reduced |
| 22 | METSERA INC | 1.2% | $5.9m | 207,581 | 84% | added | |
| 23 | ELUT ELUTIA INC | 1.1% | $5.5m | 2,761,684 | 3% | added | |
| 24 | CGEN COMPUGEN LTD | Healthcare | 1.1% | $5.4m | 3,033,879 | 5% | added |
| 25 | TELA TELA BIO INC | 1.1% | $5.4m | 2,779,795 | 0% | held | |
| 26 | ABEO ABEONA THERAPEUTICS INC | Healthcare | 1.1% | $5.2m | 917,898 | – | new |
| 27 | CDTX CIDARA THERAPEUTICS INC | 1.0% | $5.1m | 103,943 | – | new | |
| 28 | CLDX CELLDEX THERAPEUTICS INC NEW | Healthcare | 0.8% | $4.0m | 198,441 | -4% | reduced |
| 29 | AARD AARDVARK THERAPEUTICS INC | 0.8% | $3.9m | 286,807 | 140% | added | |
| 30 | MLTX MOONLAKE IMMUNOTHERAPEUTICS | Healthcare | 0.8% | $3.9m | 82,023 | – | new |
| 31 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 0.8% | $3.8m | 402,964 | -69% | reduced |
| 32 | GPCR STRUCTURE THERAPEUTICS INC | Healthcare | 0.7% | $3.6m | 175,636 | -7% | reduced |
| 33 | CERS CERUS CORP | Healthcare | 0.7% | $3.5m | 2,488,291 | 1% | added |
| 34 | ERAS ERASCA INC | Healthcare | 0.7% | $3.3m | 2,569,591 | -65% | reduced |
| 35 | CMPX COMPASS THERAPEUTICS INC | 0.7% | $3.2m | 1,249,781 | 43% | added | |
| 36 | SION SIONNA THERAPEUTICS INC | 0.7% | $3.2m | 186,015 | 63% | added | |
| 37 | BENITEC BIOPHARMA INC | 0.6% | $3.0m | 253,234 | 1% | added | |
| 38 | TRVI TREVI THERAPEUTICS INC | Healthcare | 0.6% | $3.0m | 539,587 | 2% | added |
| 39 | QURE UNIQURE NV | 0.6% | $2.8m | 202,565 | -0% | held | |
| 40 | KINIKSA PHARMACEUTICALS INTL | 0.4% | $2.1m | 75,959 | -14% | reduced | |
| 41 | ORKA ORUKA THERAPEUTICS INC | Healthcare | 0.4% | $1.9m | 165,389 | – | new |
| 42 | DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 0.4% | $1.8m | 95,806 | -50% | reduced |
| 43 | TRML TOURMALINE BIO INC | 0.4% | $1.7m | 109,257 | – | new | |
| 44 | MLYS MINERALYS THERAPEUTICS INC | Healthcare | 0.3% | $1.6m | 115,282 | -66% | reduced |
| 45 | KOD KODIAK SCIENCES INC | Healthcare | 0.3% | $1.5m | 401,540 | -9% | reduced |
| 46 | DCTH DELCATH SYS INC | 0.3% | $1.4m | 103,026 | -46% | reduced | |
| 47 | MERSANA THERAPEUTICS INC | 0.2% | $926.0k | 3,128,421 | 1% | added | |
| 48 | RADIOPHARM THERANOSTICS LTD | 0.2% | $869.6k | 187,406 | 0% | held | |
| 49 | MODULAR MED INC | 0.1% | $529.2k | 710,363 | -26% | reduced | |
| 50 | PRAX PRAXIS PRECISION MEDICINES I | Healthcare | 0.1% | $420.5k | 10,000 | -94% | reduced |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.